P
Padmanee Sharma
Researcher at University of Texas MD Anderson Cancer Center
Publications - 300
Citations - 41764
Padmanee Sharma is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Ipilimumab & Nivolumab. The author has an hindex of 67, co-authored 266 publications receiving 29799 citations. Previous affiliations of Padmanee Sharma include Memorial Sloan Kettering Cancer Center.
Papers
More filters
Journal ArticleDOI
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Robert J. Motzer,Bernard Escudier,David F. McDermott,Saby George,Hans J. Hammers,Sandhya Srinivas,Scott S. Tykodi,Jeffrey A. Sosman,Giuseppe Procopio,Elizabeth R. Plimack,Daniel Castellano,Toni K. Choueiri,Howard Gurney,Frede Donskov,Petri Bono,John Wagstaff,Thomas Gauler,Takeshi Ueda,Yoshihiko Tomita,Fabio A.B. Schutz,Christian Kollmannsberger,James Larkin,Alain Ravaud,Jason S. Simon,Li-an Xu,Ian M. Waxman,Padmanee Sharma +26 more
TL;DR: Overall survival was longer and fewer grade 3 or 4 adverse events occurred with nivolumab than with everolimus among patients with previously treated advanced renal-cell carcinoma.
Journal ArticleDOI
The future of immune checkpoint therapy
Padmanee Sharma,James P. Allison +1 more
TL;DR: The way forward for this class of novel agents lies in the ability to understand human immune responses in the tumor microenvironment, which will provide valuable information regarding the dynamic nature of the immune response and regulation of additional pathways that will need to be targeted through combination therapies to provide survival benefit for greater numbers of patients.
Journal ArticleDOI
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy.
TL;DR: As the molecular mechanisms of resistance to immunotherapy are elucidated, actionable strategies to prevent or treat them may be derived to improve clinical outcomes for patients.
Journal ArticleDOI
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
Robert J. Motzer,Nizar M. Tannir,David F. McDermott,Osvaldo Arén Frontera,Bohuslav Melichar,Toni K. Choueiri,Elizabeth R. Plimack,Philippe Barthélémy,Camillo Porta,Saby George,Thomas Powles,Frede Donskov,V. Neiman,V. Neiman,Christian Kollmannsberger,Pamela Salman,Howard Gurney,Robert E. Hawkins,Alain Ravaud,Marc-Oliver Grimm,Sergio Bracarda,Carlos H. Barrios,Yoshihiko Tomita,Daniel Castellano,Brian I. Rini,Allen C. Chen,Sabeen Mekan,M. Brent McHenry,Megan Wind-Rotolo,Justin Doan,Padmanee Sharma,Hans J. Hammers,Hans J. Hammers,Bernard Escudier +33 more
TL;DR: Overall survival and objective response rates were significantly higher with nivolumab plus ipilimumab than with sunitinib among intermediate‐ and poor‐risk patients with previously untreated advanced renal‐cell carcinoma.
Journal ArticleDOI
Depletion of Carcinoma-Associated Fibroblasts and Fibrosis Induces Immunosuppression and Accelerates Pancreas Cancer with Reduced Survival.
Berna C. Özdemir,Berna C. Özdemir,Tsvetelina Pentcheva-Hoang,Julienne L. Carstens,Xiaofeng Zheng,Chia Chin Wu,Tyler R. Simpson,Hanane Laklai,Hikaru Sugimoto,Hikaru Sugimoto,Christoph Kahlert,Christoph Kahlert,Sergey V. Novitskiy,Ana De Jesus-Acosta,Padmanee Sharma,Pedram Heidari,Umar Mahmood,Lynda Chin,Harold L. Moses,Valerie M. Weaver,Anirban Maitra,James P. Allison,Valerie S. LeBleu,Valerie S. LeBleu,Raghu Kalluri,Raghu Kalluri +25 more
TL;DR: Although myofibroblast-depleted tumors did not respond to gemcitabine, anti-CTLA4 immunotherapy reversed disease acceleration and prolonged animal survival, and underscores the need for caution in targeting carcinoma-associated fibroblasts in PDAC.